Evgen Pharma PLC Appointment of Chief Business Officer (9197S)
22 Marzo 2021 - 01:00AM
UK Regulatory
TIDMEVG
RNS Number : 9197S
Evgen Pharma PLC
22 March 2021
Evgen Pharma Plc
("Evgen" or "the Company")
Appointment of Chief Business Officer
Evgen (AIM: EVG), a clinical stage drug development company
focused on the treatment of cancer, inflammation and acute
respiratory distress syndrome, announces that Helen Kuhlman PhD
will be joining the Company as Chief Business Officer effective
from 1 April 2021.
Dr Kuhlman has over 20 years' experience in government funding
and equity investment together with scientific and business roles
in public and private R&D-based biotechnology companies. She
joins Evgen from the Development Bank of Wales where she was
responsible for equity investment in technology companies and for
managing investments in the bank's portfolio companies. Prior to
that Helen was Vice-President of Corporate Development at Chronos
Therapeutics Ltd and was previously at Innovate UK where she
created and delivered the GBP180m Biomedical Catalyst competitive
grant scheme funded by the UK government. Dr Kuhlman holds a PhD in
physiology and pharmacology from the University of Leicester,
UK.
Dr Huw Jones CEO of Evgen commented: "We are delighted to
appoint Helen to a key senior role within the Company as we
increase our focus on potential partnering activities for SFX-01.
Helen will also have a key role within the team in providing a
commercial focus on our indication selection, horizon scanning and
competitor intelligence activities."
The information communicated in this announcement is inside
information for the purposes of Article 7 of EU Regulation
596/2014.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at Alderley Park, Cheshire, and its registered office
is at the Liverpool Science Park, Liverpool. It is listed on the
AIM market of the London Stock Exchange and trades under the ticker
symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFSFIUEFSEID
(END) Dow Jones Newswires
March 22, 2021 03:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024